Autonomic & Pupil Pharmacology

Overview

Pupil size and accommodation are governed by two independent, antagonist smooth muscles. The iris dilator sits under sympathetic (alpha-1 adrenergic) control; the iris sphincter and ciliary muscle both answer to parasympathetic (muscarinic) input instead. Every drug on this page acts on one side of that pair: it stimulates the dilator, blocks the sphincter and ciliary muscle, or stimulates the sphincter directly. The resulting clinical categories follow from that split: mydriatics, cycloplegics, and miotics are named for which muscle and receptor type each drug targets.

Mydriatic Agents

Mydriatics dilate the pupil by one of two mechanistically distinct routes: stimulating the iris dilator directly (sympathomimetics), or blocking the iris sphincter (anticholinergics). The anticholinergic route always brings cycloplegia along with it, since the same muscarinic blockade paralyzes the ciliary muscle too (see below). Phenylephrine is the prototype sympathomimetic mydriatic. As a direct alpha-1 adrenergic agonist, it stimulates the iris dilator without touching the ciliary muscle, so the pupil dilates while accommodation stays intact. That makes it the drug of choice whenever dilation without cycloplegia is the goal: a routine fundus exam in an adult who still needs to read afterward, for instance.

Phenylephrine's systemic risk traces to the same receptor pharmacology. At the 10% concentration, enough drug is absorbed systemically, via the same nasolacrimal route covered on the Ocular Drug Delivery Routes page, to produce meaningful alpha-1-mediated vasoconstriction and an acute rise in blood pressure. That matters most in elderly or cardiovascular patients, for whom the lower 2.5% concentration dilates just as well with less systemic exposure.

Cycloplegic Agents

Cycloplegics are anticholinergic (antimuscarinic) agents that block muscarinic M3 receptors on both the iris sphincter and the ciliary muscle. Mydriasis and cycloplegia (paralysis of accommodation) result together, two effects of the same receptor blockade. That pairing is why cycloplegic refraction is the standard technique for measuring refractive error accurately in children: a child's strong accommodative reserve can otherwise mask hyperopia during a routine manifest refraction (see the Refractive Errors page's discussion of latent hyperopia).

The cycloplegics in clinical use differ substantially in duration and depth of effect, and that difference is what drives which agent gets chosen for which purpose:

• Tropicamide: short-acting (effect resolves in roughly 4–6 hours), the standard choice for routine diagnostic dilation where rapid recovery matters.
• Cyclopentolate 1%: intermediate duration (roughly 6–24 hours) and the practical standard for routine pediatric cycloplegic refraction. It provides good, though not maximal, cycloplegia without the prolonged photophobia and near blur that atropine's much longer duration would cause.
• Atropine 1%: the longest-acting agent, with cycloplegia and mydriasis persisting 7 to 14 days, and the one giving the most complete cycloplegia (residual accommodation under roughly 0.5 D). That makes it the preferred agent when complete cycloplegia genuinely matters, as in an esotropia workup or suspected significant latent hyperopia, even though its duration makes it impractical for routine use. Its long duration is also put to therapeutic use outside refraction, as penalization therapy in amblyopia treatment.
• Homatropine 2%: sits between cyclopentolate and atropine, with cycloplegia lasting roughly 1 to 3 days. Its main modern role is therapeutic rather than diagnostic: cycloplegic pain relief in acute anterior uveitis, where a duration long enough to control ciliary spasm but short enough to keep the pupil mobile lowers the risk of posterior synechiae that atropine's week-long effect would carry.

Atropine, and less commonly the other cycloplegics, can also be absorbed systemically. Children are most at risk, since their smaller body mass concentrates a given topical dose more. The result is a recognizable systemic anticholinergic toxidrome: dry mouth, flushed and dry skin, tachycardia, and in severe cases urinary retention or hallucinations, classically remembered as "hot as a hare, dry as a bone, red as a beet."

Miotic Agents

Pilocarpine, a direct-acting muscarinic agonist, produces the opposite pupil effect from the cycloplegics above. It stimulates the same M3 receptors rather than blocking them, contracting the iris sphincter (miosis) and the ciliary muscle (accommodation) instead of paralyzing either.

In acute angle-closure glaucoma, pilocarpine-induced miosis pulls the peripheral iris away from the trabecular meshwork, mechanically reopening the drainage angle and restoring aqueous outflow. It is adjunctive to IOP-lowering medication and definitive laser iridotomy, not a substitute for either, and it loses effectiveness at very high IOP, where the ischemic iris sphincter stops responding to the drug at all. A separate hazard shows up when posterior synechiae (iris-to-lens adhesions) are already present: miosis can then draw the pupillary margin tightly against the lens and worsen pupillary block instead of relieving it. Synechiolysis with mydriatics or laser has to come first in that setting; miotic use may be contraindicated outright.

Pilocarpine's ciliary muscle contraction also causes a distinctive refractive side effect, pilocarpine-induced pseudomyopia. Sustained ciliary spasm increases lens curvature and total ocular power, simulating a myopic shift. The shift resolves once cycloplegia is induced, which confirms its pharmacologic rather than true axial origin. That same accommodative spasm, together with miosis-related dim vision and brow ache, is why chronic pilocarpine has largely been replaced for long-term glaucoma treatment by better-tolerated drug classes, especially in younger patients who still have active accommodation to lose (see the Anti-Glaucoma Pharmacology page).

One more agent belongs here, even though it runs the sphincter/ciliary logic in reverse. Low-dose atropine (0.01%), an anticholinergic rather than a miotic, has become the most studied pharmacologic agent for slowing pediatric myopia progression. At this very low concentration it produces minimal cycloplegia or mydriasis, so its myopia-control effect can't be simple ciliary relaxation. The leading mechanistic hypothesis instead points to non-M3 muscarinic receptor subtypes (M1/M4) acting on retinal dopamine release and downstream scleral remodeling. The fuller myopia-control discussion lives on the Refractive Errors page referenced above.

Pilocarpine binds the muscarinic receptor directly. A second class of miotics, the indirect-acting (cholinesterase-inhibitor) agents, instead blocks the breakdown of endogenous acetylcholine. Echothiophate iodide is the classic example, still used occasionally in aphakic glaucoma though it has largely fallen out of routine use. Its irreversible inhibition of acetylcholinesterase depletes plasma pseudocholinesterase with chronic use, the same enzyme that clears succinylcholine, so a patient on long-term echothiophate who later needs general anesthesia can develop prolonged postoperative apnea. Chronic use can also produce iris pigment epithelial cysts at the pupillary margin. These usually regress with discontinuation of the drug or adjunctive topical phenylephrine, and rarely need excision. Carbachol combines both mechanisms in one drug, direct muscarinic and nicotinic stimulation plus a secondary anticholinesterase effect. It is used intracamerally at the close of cataract surgery for rapid, sustained miosis, with IOP control lasting up to 24 hours into the postoperative period.

Pilocarpine also serves a diagnostic role outside glaucoma treatment. A dilated, poorly reactive pupil with no other neurologic signs that fails to constrict to full-strength 1% pilocarpine is pharmacologically dilated, its muscarinic receptors already blocked by an anticholinergic agent rather than the sphincter simply lacking a nerve signal. Scopolamine transdermal patches, nasal decongestant sprays, and tropane alkaloids in plants like Jimsonweed (Datura stramonium) are common sources of inadvertent exposure. A pupil affected by true denervation, from a compressive third nerve palsy or an Adie tonic pupil, still has intact receptors and constricts to that same 1% concentration. Adie tonic pupil has its own more specific test: a dilute 0.1% pilocarpine drop, too weak to affect a normally innervated pupil, constricts the Adie pupil because denervation supersensitivity has upregulated its receptors, the same phenomenon apraclonidine exploits in Horner syndrome testing below.

Mydriatic Reversal Agents

Dapiprazole, an alpha-adrenergic blocking agent, reverses pharmacologic (sympathomimetic) mydriasis by blocking the iris dilator muscle directly. It antagonizes the exact receptor phenylephrine stimulated to cause dilation in the first place. It is much less effective against anticholinergic mydriasis, from tropicamide, for example, because those agents work by blocking the sphincter rather than stimulating the dilator. Dapiprazole's dilator blockade does nothing to restore sphincter function in that case. Reversing anticholinergic mydriasis instead calls for a direct muscarinic agonist, pilocarpine 1 to 2%, which stimulates the sphincter to constrict and counteracts the anticholinergic block on the same receptor rather than acting on the antagonist muscle.

Pharmacologic Testing for Horner Syndrome

Horner syndrome, the triad of miosis, ptosis, and anhidrosis from disruption of the ocular sympathetic pathway, is unusual among neurologic diagnoses in having a validated pharmacologic test sequence. The sympathetic pathway to the iris dilator runs through a three-neuron chain (central, preganglionic, postganglionic), and where along that chain the lesion sits changes how the dilator responds to specific drugs.

Cocaine testing exploits a mechanism unlike any other drug on this page: it blocks noradrenaline reuptake at sympathetic nerve terminals, potentiating whatever endogenous noradrenaline is already being released. In a normal eye that potentiation produces mydriasis. In a Horner eye, where the pre- or postganglionic neuron is disrupted and releasing little noradrenaline to begin with, there is little transmitter left for cocaine to potentiate, so the pupil fails to dilate. Cocaine testing confirms that a Horner syndrome is present. It says nothing about which neuron is affected.

Apraclonidine testing works through a different mechanism, and unlike cocaine it actively reverses the anisocoria rather than just failing to enhance it. Apraclonidine is primarily an alpha-2 agonist with a lesser alpha-1 effect. Chronic sympathetic denervation in a Horner eye upregulates alpha-1 receptors on the iris dilator, a phenomenon called denervation supersensitivity, so apraclonidine's normally minor alpha-1 effect becomes clinically significant there and dilates the Horner pupil. In the normal fellow eye, its dominant alpha-2 effect produces slight miosis instead. The net result flips the anisocoria pattern seen at baseline.

Once Horner syndrome is confirmed, hydroxyamphetamine localizes the lesion to the postganglionic (third-order) neuron specifically. It releases stored noradrenaline from intact postganglionic nerve terminals. If that neuron is intact, meaning the lesion is first- or second-order, enough stored transmitter is present to be released and the pupil dilates normally. If the postganglionic neuron itself is damaged, there is no stored noradrenaline left to release, and the pupil fails to dilate. That single test localizes the lesion pharmacologically.

One more pediatric safety point belongs here, even though it's unrelated to the Horner sequence. Brimonidine, an alpha-2 agonist used for IOP lowering, is contraindicated in infants and young children: their immature blood-brain barrier lets it cross into the CNS more readily than in adults, risking central nervous system and respiratory depression, bradycardia, hypotension, and even apnea. None of the other autonomic pupil drugs on this page carry a comparable pediatric risk.

Apraclonidine also has a use with nothing to do with Horner testing. Its alpha-2 effect blunts the acute intraocular pressure spike that follows anterior segment laser procedures, studied most closely after Nd:YAG posterior capsulotomy. A single drop given before the laser and again afterward keeps pressure from climbing in the following hours; in some trials the treated eye's pressure actually came in below baseline instead of rising. For laser trabeculoplasty the same prophylactic idea applies, though there pilocarpine performs at least as well.

Related Topics

Continue exploring Basic Sciences: